Advanced Renal Cell Carcinoma: Integrating Emerging Therapies Into Clinical Practice

In this segment, the discussion focuses on how clinicians incorporate emerging therapies into routine practice for advanced renal cell carcinoma. Dr. Brian Rini emphasizes a cautious and evidence-based approach, typically adopting new treatments after regulatory approval and careful evaluation of clinical data. He highlights the importance of individualized decision-making, noting that treatment selection is guided by a benefit–risk assessment tailored to each patient rather than broad application across all cases. Dr. Elizabeth Plimack adds that while new therapies are introduced gradually in clinical practice, it is important for clinicians to remain open and adaptable to evolving evidence. She underscores the value of early clinical experience, often gained through participation in clinical trials, as well as peer-to-peer learning in refining treatment strategies. The segment highlights that integrating new therapies in advanced renal cell carcinoma requires a balance between innovation, clinical judgment, and shared experience to optimize patient outcomes.